{"url_path":"/sec/bcax/8-k/2026-05-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/0001628280-26-037377-index.html","accession_number":"0001628280-26-037377","cik":"0002023658","ticker":"BCAX","issuer_name":"Bicara Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2023658/0001628280-26-037377-index.html","primary_entity_key":"0002023658","primary_entity_name":"Bicara Therapeutics Inc."},"word_count":56,"has_tables":true,"body_markdown":"Item 8.01 - Other Events.\n\nOn May 21, 2026, Bicara Therapeutics Inc. issued a press release entitled “Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference."}